Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
<p><strong>Objective:</strong> To determine persistence of treatment with secukinumab across its different indications.</p><p><strong>Method:</strong> This is a retrospective descriptive observational study including adult patients treated with secukinuma...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Grupo Aula Médica
2021-01-01
|
Series: | Farmacia Hospitalaria |
Subjects: | |
Online Access: | http://www.aulamedica.es/fh/pdf/11465.pdf |
id |
doaj-c98f6a32b78c453ea59fa3675c136e38 |
---|---|
record_format |
Article |
spelling |
doaj-c98f6a32b78c453ea59fa3675c136e382021-01-14T12:16:55ZengGrupo Aula MédicaFarmacia Hospitalaria1130-63432171-86952021-01-01451162110.7399/fh.11465Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitisElena Conesa-Nicolás0María Henar García-Lagunar1Sara Núñez-Bracamonte2María Sergia García-Simón3María Carmen Mira-Sirvent4Pharmacy Department, Hospital General Universitario Santa Lucía, Cartagena (Murcia). SpainPharmacy Department, Hospital General Universitario Santa Lucía, Cartagena (Murcia). SpainPharmacy Department, Hospital General Universitario Santa Lucía, Cartagena (Murcia). SpainPharmacy Department, Hospital General Universitario Santa Lucía, Cartagena (Murcia). SpainPharmacy Department, Hospital General Universitario Santa Lucía, Cartagena (Murcia). Spain<p><strong>Objective:</strong> To determine persistence of treatment with secukinumab across its different indications.</p><p><strong>Method:</strong> This is a retrospective descriptive observational study including adult patients treated with secukinumab in its different indications from the drug’s introduction in November 2015 to October 2019. The variables included were sex; age; diagnosis; initiation date; line of treatment; number of patients who discontinued treatment and reason for discontinuation; overall persistence at 12 months; distribution of patients; and persistence according to indication, line of treatment and reason for suspension.</p><p><strong>Results:</strong> One-hundred forty-three patients were started on secukinumab, but only patients who had been in treatment at least 12 months before the end of the study were included. Mean patient age was 49.8 years (±12.6); 52.9% were men. Fifty-six patients (53.8%) had discontinued treatment by the end of the study, with a mean duration of treatment of 12.7 months (±10.2). The other patients (n = 48) continued with their therapy. Mean duration of treatment in these patients was 25.7 months (±9.9). Overall persistence at 12 months was 10.0 months (±3.3) with a discontinuation rate at 12 months of 31.7%. Persistence at 12 months was 10.7 months (±2.9) for patients with psoriasis, 9.7 months (±3.4) for patients with psoriatic arthritis, and 8.8 months (±3.8) for those with ankylosing spondylitis. Of the 48 patients who continued with their treatment after completion of the study, 22 (45.8%) received the drug as first-line treatment. Of the 56 discontinuations, 15 (26.8%) were due to primary failure (persistence: 3.8 months [±1.1]) and 27 (48.2%) were due to secondary failure (persistence: 18.6 months [±9.6]). Persistence in patients who continued treatment was higher in psoriasis (28.8 months [±10.3]). In those who discontinued due to secondary failure it was higher in the group with ankylosing spondylitis (28.0 months [±4.2]). Persistence among patients on first-line secukinumab was higher than for other patients: 21.2 months (±7.2) if they stayed on treatment, 3.5 months (±0.5) if they presented with primary treatment failure, and 8.3 months (±2.5) in those with secondary treatment failure.</p><p><strong>Conclusions:</strong> Our data show slightly higher persistence levels in patients with psoriasis and lower discontinuation rates in those without previous exposure to biological therapy. Long-term studies are needed to confirm these findings and to gain a better understanding of the factors that can influence persistence of secukinumab.</p><p> </p> http://www.aulamedica.es/fh/pdf/11465.pdfpersistencebiological therapysecukinumabpsoriatic arthritisankylosing spondylitispsoriasis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena Conesa-Nicolás María Henar García-Lagunar Sara Núñez-Bracamonte María Sergia García-Simón María Carmen Mira-Sirvent |
spellingShingle |
Elena Conesa-Nicolás María Henar García-Lagunar Sara Núñez-Bracamonte María Sergia García-Simón María Carmen Mira-Sirvent Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis Farmacia Hospitalaria persistence biological therapy secukinumab psoriatic arthritis ankylosing spondylitis psoriasis |
author_facet |
Elena Conesa-Nicolás María Henar García-Lagunar Sara Núñez-Bracamonte María Sergia García-Simón María Carmen Mira-Sirvent |
author_sort |
Elena Conesa-Nicolás |
title |
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis |
title_short |
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis |
title_full |
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis |
title_fullStr |
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis |
title_full_unstemmed |
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis |
title_sort |
persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis |
publisher |
Grupo Aula Médica |
series |
Farmacia Hospitalaria |
issn |
1130-6343 2171-8695 |
publishDate |
2021-01-01 |
description |
<p><strong>Objective:</strong> To determine persistence of treatment with secukinumab across its different indications.</p><p><strong>Method:</strong>
This is a retrospective descriptive observational study including adult patients treated with secukinumab in its different indications from the drug’s
introduction in November 2015 to October 2019. The variables included were sex; age; diagnosis; initiation date; line of treatment; number of patients who
discontinued treatment and reason for discontinuation; overall persistence at 12 months; distribution of patients; and persistence according to indication, line
of treatment and reason for suspension.</p><p><strong>Results:</strong> One-hundred forty-three patients were started on secukinumab, but only
patients who had been in treatment at least 12 months before the end of the study were included. Mean patient age was 49.8 years (±12.6); 52.9% were
men. Fifty-six patients (53.8%) had discontinued treatment by the end of the study, with a mean duration of treatment of 12.7 months (±10.2). The other
patients (n = 48) continued with their therapy. Mean duration of treatment in these patients was 25.7 months (±9.9). Overall persistence at 12 months was
10.0 months (±3.3) with a discontinuation rate at 12 months of 31.7%. Persistence at 12 months was 10.7 months (±2.9) for patients with psoriasis, 9.7
months (±3.4) for patients with psoriatic arthritis, and 8.8 months (±3.8) for those with ankylosing spondylitis. Of the 48 patients who continued with their
treatment after completion of the study, 22 (45.8%) received the drug as first-line treatment. Of the 56 discontinuations, 15 (26.8%) were due to
primary failure (persistence: 3.8 months [±1.1]) and 27 (48.2%) were due to secondary failure (persistence: 18.6 months [±9.6]). Persistence in patients who
continued treatment was higher in psoriasis (28.8 months [±10.3]). In those who discontinued due to secondary failure it was higher in the group with
ankylosing spondylitis (28.0 months [±4.2]). Persistence among patients on first-line secukinumab was higher than for other patients: 21.2 months (±7.2) if
they stayed on treatment, 3.5 months (±0.5) if they presented with primary treatment failure, and 8.3 months (±2.5) in those with secondary treatment
failure.</p><p><strong>Conclusions:</strong> Our data show slightly higher persistence levels in patients with psoriasis and lower discontinuation rates in
those without previous exposure to biological therapy. Long-term studies are needed to confirm these findings and to gain a better understanding of the
factors that can influence persistence of secukinumab.</p><p> </p>
|
topic |
persistence biological therapy secukinumab psoriatic arthritis ankylosing spondylitis psoriasis |
url |
http://www.aulamedica.es/fh/pdf/11465.pdf |
work_keys_str_mv |
AT elenaconesanicolas persistenceofsecukinumabinpatientswithpsoriasispsoriaticarthritisandankylosingspondylitis AT mariahenargarcialagunar persistenceofsecukinumabinpatientswithpsoriasispsoriaticarthritisandankylosingspondylitis AT saranunezbracamonte persistenceofsecukinumabinpatientswithpsoriasispsoriaticarthritisandankylosingspondylitis AT mariasergiagarciasimon persistenceofsecukinumabinpatientswithpsoriasispsoriaticarthritisandankylosingspondylitis AT mariacarmenmirasirvent persistenceofsecukinumabinpatientswithpsoriasispsoriaticarthritisandankylosingspondylitis |
_version_ |
1724338268552560640 |